Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Ovarian Neoplasms 2Glioblastoma 2Squamous Cell Carcinoma of Head and Neck 1Head and Neck Neoplasms 1Glioma 1Advanced Malignant Solid Neoplasm 1Advanced Malignancies 1

Interventions

Paclitaxel 69Bevacizumab 62Carboplatin 53pembrolizumab 46olaparib 32Specimen Handling 27Gemcitabine 27Cyclophosphamide 26Magnetic Resonance Spectroscopy 24liposomal doxorubicin 22Cisplatin 21niraparib 20Taxes 18Nivolumab 18fludarabine 17Topotecan 17Biopsy 17Doxorubicin 14Immunoglobulin G 12Fulvestrant 12Disulfides 12Oxaliplatin 10mirvetuximab soravtansine 9durvalumab 9aldesleukin 9Surveys and Questionnaires 9Ipilimumab 9Fluorouracil 9Blood Specimen Collection 9cemiplimab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Ovarian Neoplasms × pamiparib × 1 year × Clear all
NCT03519230 2026-03-16

Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer

BeOne Medicines

Phase 3 Active not recruiting
224 enrolled
Gynecologic

Ovarian Neoplasms

NCT05494580 2026-03-10

Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

Sun Yat-sen University

Phase 1/2 Completed
29 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡